Were Jeri Williams’ AXON share sales made under a trading plan?

Yes, the reported AXON share sales used a Rule 10b5-1 plan. The Form 4 notes that the transactions on June 1, 2026 were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.

Axon director sells 629 shares after stock grant

Q: How many AXON shares did Jeri Williams sell and at what prices?

Williams sold a total of 629 Axon shares. She sold 223 shares at $455.45 per share and 406 shares at a weighted average price of $477.4333 per share, with the latter executed in multiple trades within a narrow pricing range.

Q: What stock award did Jeri Williams receive from Axon (AXON)?

Williams received 611 time-vested restricted stock units. The units were granted under Axon’s Amended and Restated 2022 Stock Incentive Plan and are scheduled to vest in full on the earlier of the one-year anniversary of the grant date or Axon’s 2027 Annual Meeting of Shareholders.

AXON ENTERPRISE, INC. director Jeri Williams reported a mix of stock award and sales.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AXON ENTERPRISE, INC. director Jeri Williams reported a mix of stock award and sales. On May 29, 2026, she received 611 time-vested restricted stock units under Axon’s Amended and Restated 2022 Stock Incentive Plan, scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the company’s 2027 Annual Meeting of Shareholders.

On June 1, 2026, she completed two open-market sales totaling 629 shares of common stock: 223 shares at $455.45 per share and 406 shares at a weighted average price of $477.4333 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following these transactions, she directly holds 1,141 shares of Axon common stock.

Insider Trade Summary 10b5-1

Net Seller: 629 shares

Net Sell 3 txns

Insider Williams Jeri

Role Director

Sold 629 shs ($295K)

Type	Security	Shares	Price	Value
Sale	Common Stock	406	$477.4333	$194K
Sale	Common Stock	223	$455.45	$102K
Grant/Award	Common Stock	611	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,141 shares (Direct)

Footnotes (3)

F1. Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan. The award is scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the date of Axon Enterprise, Inc.'s 2027 Annual Meeting of Shareholders.
F2. The transaction was executed in multiple trades at prices ranging from $477.03 to $477.60. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

Key Figures

Shares sold (total): 629 shares First sale: 223 shares at $455.45/share Second sale: 406 shares at $477.4333/share +3 more

6 metrics

Shares sold (total) 629 shares Open-market sales of common stock on June 1, 2026

First sale 223 shares at $455.45/share Open-market sale of Axon common stock on June 1, 2026

Second sale 406 shares at $477.4333/share Weighted average price across multiple trades on June 1, 2026

RSUs granted 611 units Time-vested restricted stock units granted on May 29, 2026

Post-transaction holdings 1,141 shares Direct Axon common stock holdings after reported transactions

Net share change -629 shares Net-sell direction from transaction summary in this Form 4

Key Terms

time-vested restricted stock units, Amended and Restated 2022 Stock Incentive Plan, weighted average sales price, Rule 10b5-1 trading plan, +1 more

5 terms

time-vested restricted stock units financial

"Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan."

Amended and Restated 2022 Stock Incentive Plan financial

"granted to the reporting person pursuant to the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan."

weighted average sales price financial

"The transaction was executed in multiple trades at prices ranging from $477.03 to $477.60. The price reported above reflects the weighted average sales price."

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Annual Meeting of Shareholders financial

"scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the date of Axon Enterprise, Inc.'s 2027 Annual Meeting of Shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AXON director Jeri Williams report in this Form 4?

Jeri Williams reported one stock award and two stock sales. She received 611 time-vested restricted stock units, then sold 629 common shares in two open-market transactions. After these moves, she directly holds 1,141 Axon common shares.

How many AXON shares did Jeri Williams sell and at what prices?

Williams sold a total of 629 Axon shares. She sold 223 shares at $455.45 per share and 406 shares at a weighted average price of $477.4333 per share, with the latter executed in multiple trades within a narrow pricing range.

What stock award did Jeri Williams receive from Axon (AXON)?

Williams received 611 time-vested restricted stock units. The units were granted under Axon’s Amended and Restated 2022 Stock Incentive Plan and are scheduled to vest in full on the earlier of the one-year anniversary of the grant date or Axon’s 2027 Annual Meeting of Shareholders.

How many AXON shares does Jeri Williams hold after these transactions?

Williams directly holds 1,141 Axon common shares after the transactions. This figure reflects the net effect of receiving 611 restricted stock units and selling 629 shares in two open-market transactions reported in the Form 4.

What does the weighted average sale price mean in Jeri Williams’ AXON filing?

The weighted average price summarizes multiple sale trades. For the 406-share sale, trades occurred between $477.03 and $477.60 per share. The reported $477.4333 is the weighted average across those individual executions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 05:25 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Williams Jeri

(Last)

(First)

(Middle)

17800 NORTH 85TH STREET

(Street)

SCOTTSDALE

ARIZONA

85255

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AXON ENTERPRISE, INC. [ AXON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		A		611⁽¹⁾	A	$0	1,770	D
Common Stock	06/01/2026		S		406	D	$477.4333⁽²⁾	1,364	D
Common Stock	06/01/2026		S⁽³⁾		223	D	$455.45	1,141	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Time-vested restricted stock units granted to the reporting person pursuant to the Axon Enterprise, Inc. Amended and Restated 2022 Stock Incentive Plan. The award is scheduled to vest in full on the earlier of the one-year anniversary of the grant date and the date of Axon Enterprise, Inc.'s 2027 Annual Meeting of Shareholders.

2. The transaction was executed in multiple trades at prices ranging from $477.03 to $477.60. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 8, 2025.

Remarks:

	/s/ Jeri Williams, by Isaiah Fields, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR